CANCIDAS Drug Patent Profile
✉ Email this page to a colleague
When do Cancidas patents expire, and when can generic versions of Cancidas launch?
Cancidas is a drug marketed by Merck and is included in one NDA.
The generic ingredient in CANCIDAS is caspofungin acetate. There are eight drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the caspofungin acetate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cancidas
A generic version of CANCIDAS was approved as caspofungin acetate by FRESENIUS KABI USA on December 30th, 2016.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CANCIDAS?
- What are the global sales for CANCIDAS?
- What is Average Wholesale Price for CANCIDAS?
Summary for CANCIDAS
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 67 |
| Clinical Trials: | 19 |
| Patent Applications: | 2,361 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for CANCIDAS |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for CANCIDAS |
| What excipients (inactive ingredients) are in CANCIDAS? | CANCIDAS excipients list |
| DailyMed Link: | CANCIDAS at DailyMed |
Recent Clinical Trials for CANCIDAS
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Cidara Therapeutics Inc. | Phase 3 |
| Cttq | Phase 2 |
| Cidara Therapeutics Inc. | Phase 2 |
Pharmacology for CANCIDAS
| Drug Class | Echinocandin Antifungal |
Paragraph IV (Patent) Challenges for CANCIDAS
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| CANCIDAS | for Injection | caspofungin acetate | 50 mg/vial and 70 mg/vial | 021227 | 1 | 2009-06-26 |
US Patents and Regulatory Information for CANCIDAS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck | CANCIDAS | caspofungin acetate | POWDER;INTRAVENOUS | 021227-001 | Jan 26, 2001 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Merck | CANCIDAS | caspofungin acetate | POWDER;INTRAVENOUS | 021227-002 | Jan 26, 2001 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CANCIDAS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Merck | CANCIDAS | caspofungin acetate | POWDER;INTRAVENOUS | 021227-001 | Jan 26, 2001 | ⤷ Sign Up | ⤷ Sign Up |
| Merck | CANCIDAS | caspofungin acetate | POWDER;INTRAVENOUS | 021227-002 | Jan 26, 2001 | ⤷ Sign Up | ⤷ Sign Up |
| Merck | CANCIDAS | caspofungin acetate | POWDER;INTRAVENOUS | 021227-001 | Jan 26, 2001 | ⤷ Sign Up | ⤷ Sign Up |
| Merck | CANCIDAS | caspofungin acetate | POWDER;INTRAVENOUS | 021227-002 | Jan 26, 2001 | ⤷ Sign Up | ⤷ Sign Up |
| Merck | CANCIDAS | caspofungin acetate | POWDER;INTRAVENOUS | 021227-001 | Jan 26, 2001 | ⤷ Sign Up | ⤷ Sign Up |
| Merck | CANCIDAS | caspofungin acetate | POWDER;INTRAVENOUS | 021227-001 | Jan 26, 2001 | ⤷ Sign Up | ⤷ Sign Up |
| Merck | CANCIDAS | caspofungin acetate | POWDER;INTRAVENOUS | 021227-002 | Jan 26, 2001 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for CANCIDAS
See the table below for patents covering CANCIDAS around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 5783294 | ⤷ Sign Up | |
| China | 1222082 | ⤷ Sign Up | |
| Germany | 69722615 | ⤷ Sign Up | |
| Israel | 108892 | Aza cyclohexapeptide compounds and antimicrobial compositions containing them | ⤷ Sign Up |
| Austria | 241999 | ⤷ Sign Up | |
| Poland | 329442 | ⤷ Sign Up | |
| Australia | 2731197 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for CANCIDAS
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0620232 | SPC/GB02/002 200210 | United Kingdom | ⤷ Sign Up | |
| 0620232 | 44/2001 | Austria | ⤷ Sign Up | PRODUCT NAME: CASPOFUNGIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE CASPOFUNGINACETAT; REGISTRATION NO/DATE: EU/01/196/001-003 20011024 |
| 0620232 | 2001/029 | Ireland | ⤷ Sign Up | PRODUCT NAME: CASPOFUNGIN, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY CASPOFUNGIN ACETATE; REGISTRATION NO/DATE: EU/1/01/196/001-003 20011024; PAEDIATRIC INV. PLAN: P/30/2008 |
| 0620232 | C300076 | Netherlands | ⤷ Sign Up | PRODUCT NAME: CASPOFUNGINE, DESGEWENST IN DE VORM VAN EEN ZUURADDITIEZOUT, IN HET BIJZONDER CASPOFUNGINE ACETAAT; REGISTRATION NO/DATE: EU/1/01/196/001-003 20011024 |
| 0620232 | CA 2002 00007 | Denmark | ⤷ Sign Up | |
| 0620232 | 01C0054 | France | ⤷ Sign Up | PRODUCT NAME: CASPOFUNGIN ACETATE; REGISTRATION NO/DATE: EU/1/01/196/001 20011024 |
| 0620232 | 08C0036 | France | ⤷ Sign Up | PRODUCT NAME: THALIDOMIDE; REGISTRATION NO/DATE: EU/1/08/443/001 20080416 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
